3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cytarabine
85
Cyclophosphamide
58
Azacitidine
57
fludarabine
52
venetoclax
41
fludarabine phosphate
41
Busulfan
30
Filgrastim
23
Whole-Body Irradiation
22
Decitabine
21
Mycophenolic Acid
20
Methotrexate
19
Mitoxantrone
18
Etoposide
18
Antilymphocyte Serum
18
Cyclosporine
17
Clofarabine
17
Tacrolimus
16
Granulocyte Colony-Stimulating Factor
16
Peripheral Blood Stem Cell Transplantation
15
Daunorubicin
15
Melphalan
13
thymoglobulin
11
Thiotepa
11
Stem Cell Transplantation
11
Interleukin-2
11
Idarubicin
10
Gemtuzumab
9
Cord Blood Stem Cell Transplantation
9
aldesleukin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myeloid, Acute
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled